1.  It may take up to FIVE MINUTES to receive your confirmation email 

2.  It is recommended that you add the meeting information from your confirmation email to your calendar because Microsoft Teams does not send reminder emails at this time 

*If you have any technical difficulties with registering:

1.  Try opening the registration link in a different web browser. Copy and paste the following link:,uNx-SAKtgUKWpDCFjOXgQw,javcFoeYYkuOtCpIoTYXjg,DiM7JYjBsEW9xRlja3sQqw,kj0FCTIu70iA_kIi7jjcWw,a6IQIF0PskK6EM9AtOcd7w?mode=read&tenantId=991ba2ea-1d0b-40b6-a6f1-9fb2f78a7d5e

2.  If problem persist, please email: 

Overview: This webinar will discuss the use of biosimilars for inflammatory diseases. The main focus will be on adalimumab for its various indications.

Topic: Biosimilars for Inflammatory Diseases: Why we all should care? 

Alvin Wells, MD, PhD, FACR, FACP
Director, Department of Rheumatology, AAMG-WI 
Assistant Clinical Professor, Medical College of WI

Ashley Kwasinski, DNP, APNP
Nurse Practitioner, Infectious Disease

At the completion of this activity, the participant should be able to:

  • Define a biosimilar medication
  • Discuss the development and approval process for a biosimilar medication
  • Discuss the implications of changing from an originator product to a biosimilar
  • Review current clinical data on the use of biosimilar medications
Session date: 
03/16/2023 - 7:00am to 8:00am CDT
  • 1.00 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
    Attendance Credit

Please login or register to take this course.